Caxton Associates LP Buys Shares of 44,565 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Caxton Associates LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 44,565 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,730,000.

Several other institutional investors and hedge funds also recently made changes to their positions in COLL. LSV Asset Management raised its position in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after acquiring an additional 248,751 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Collegium Pharmaceutical by 1,475.5% in the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after buying an additional 188,347 shares during the period. Federated Hermes Inc. grew its holdings in shares of Collegium Pharmaceutical by 76.0% in the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after buying an additional 91,911 shares during the period. Third Avenue Management LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $2,558,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Collegium Pharmaceutical by 119.6% in the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after buying an additional 79,823 shares during the period.

Collegium Pharmaceutical Stock Up 12.6 %

NASDAQ COLL traded up $4.41 on Tuesday, reaching $39.30. The company had a trading volume of 776,836 shares, compared to its average volume of 459,174. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 15.63 and a beta of 0.93. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. Collegium Pharmaceutical, Inc. has a 1-year low of $20.95 and a 1-year high of $40.95. The company’s fifty day moving average is $32.65 and its 200-day moving average is $34.63.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The company had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. On average, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the sale, the director now directly owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold 105,502 shares of company stock valued at $3,540,796 in the last three months. 3.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on COLL. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a report on Tuesday. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price target for the company from $41.00 to $44.00 in a report on Friday, June 7th. Piper Sandler lowered shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a report on Friday, May 10th. Finally, HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.